<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01119443</url>
  </required_header>
  <id_info>
    <org_study_id>248.677</org_study_id>
    <nct_id>NCT01119443</nct_id>
  </id_info>
  <brief_title>Bioequivalence of Pramipexole Extended Release (PPX ER) 1.5mg x 1 Tablet Once Daily (q.d.) vs. PPX ER 0.375mg x 4 Tablets Under Fasted and Fed Conditions in Japanese Healthy Volunteers</brief_title>
  <official_title>A Multiple Dose Study With Increasing Dose for Pramipexole Extended Release (ER) Tablet (0.375 mg q.d. to 1.5 mg q.d.) in Two-way Cross-over Comparison to Investigate the Bioequivalence of 1.5 mg ER x 1 Tablet q.d. Versus 0.375 mg ER x 4 Tablets q.d. Under Fasted and Fed Conditions in Japanese Healthy Male Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      Bioequivalence between PPX ER 1.5 mg x 1 tablet q.d. and 0.375 mg PPX ER x 4 tablets q.d.
      under fasted and fed conditions Food effect of 1.5 mg ER x 1 tablet q.d.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2010</start_date>
  <primary_completion_date type="Actual">June 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUCτ,ss (Fed Conditions)</measure>
    <time_frame>Serial pharmacokinetic blood samples collected before drug administration, 1, 2, 2.5, 3, 4, 6, 8, 10, 12, and 23.833 hours after drug administration</time_frame>
    <description>Area under the concentration-time curve of the analyte in plasma at steady state over a uniform dosing interval τ</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax,ss (Fed Conditions)</measure>
    <time_frame>Serial pharmacokinetic blood samples collected before drug administration, 1, 2, 2.5, 3, 4, 6, 8, 10, 12, and 23.833 hours after drug administration</time_frame>
    <description>maximum measured concentration of the analyte in plasma at steady state over a uniform dosing interval τ</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUCτ,ss (Fasted Conditions)</measure>
    <time_frame>Serial pharmacokinetic blood samples collected before drug administration, 1, 2, 2.5, 3, 4, 6, 8, 10, 12, and 23.833 hours after drug administration</time_frame>
    <description>Area under the concentration-time curve of the analyte in plasma at steady state over a uniform dosing interval τ</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax,ss (Fasted Conditions)</measure>
    <time_frame>Serial pharmacokinetic blood samples collected before drug administration, 1, 2, 2.5, 3, 4, 6, 8, 10, 12, and 23.833 hours after drug administration</time_frame>
    <description>maximum measured concentration of the analyte in plasma at steady state over a uniform dosing interval τ</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cτ,ss (Fed Conditions)</measure>
    <time_frame>pharmacokinetic blood samples collected at τ (23.833 hours) after drug administration</time_frame>
    <description>Concentration of the analyte in plasma at time τ at steady state</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmin,ss (Fed Conditions)</measure>
    <time_frame>Serial pharmacokinetic blood samples collected before drug administration, 1, 2, 2.5, 3, 4, 6, 8, 10, 12, and 23.833 hours after drug administration</time_frame>
    <description>Minimum measured concentration of the analyte in plasma at steady state over a uniform dosing interval τ</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax,ss (Fed Conditions)</measure>
    <time_frame>Serial pharmacokinetic blood samples collected before drug administration, 1, 2, 2.5, 3, 4, 6, 8, 10, 12, and 23.833 hours after drug administration</time_frame>
    <description>Time from dosing to the maximum measured concentration of the analyte in plasma at steady state over a uniform dosing interval τ</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>λz,ss (Fed Conditions)</measure>
    <time_frame>Serial pharmacokinetic blood samples collected before drug administration, 1, 2, 2.5, 3, 4, 6, 8, 10, 12, and 23.833 hours after drug administration</time_frame>
    <description>Terminal rate constant of the analyte in plasma at steady state</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2,ss (Fed Conditions)</measure>
    <time_frame>Serial pharmacokinetic blood samples collected before drug administration, 1, 2, 2.5, 3, 4, 6, 8, 10, 12, and 23.833 hours after drug administration</time_frame>
    <description>Terminal half-life of the analyte in plasma at steady state</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MRTpo,ss (Fed Conditions)</measure>
    <time_frame>Serial pharmacokinetic blood samples collected before drug administration, 1, 2, 2.5, 3, 4, 6, 8, 10, 12, and 23.833 hours after drug administration</time_frame>
    <description>Mean residence time of the analyte in the body at steady state after oral administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cτ,ss (Fasted Conditions)</measure>
    <time_frame>pharmacokinetic blood samples collected at τ (23.833 hours) after drug administration</time_frame>
    <description>Concentration of the analyte in plasma at time τ at steady state</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmin,ss (Fasted Conditions)</measure>
    <time_frame>Serial pharmacokinetic blood samples collected before drug administration, 1, 2, 2.5, 3, 4, 6, 8, 10, 12, and 23.833 hours after drug administration</time_frame>
    <description>Minimum measured concentration of the analyte in plasma at steady state over a uniform dosing interval τ</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax,ss (Fasted Conditions)</measure>
    <time_frame>Serial pharmacokinetic blood samples collected before drug administration, 1, 2, 2.5, 3, 4, 6, 8, 10, 12, and 23.833 hours after drug administration</time_frame>
    <description>Time from dosing to the maximum measured concentration of the analyte in plasma at steady state over a uniform dosing interval τ</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>λz,ss (Fasted Conditions)</measure>
    <time_frame>Serial pharmacokinetic blood samples collected before drug administration, 1, 2, 2.5, 3, 4, 6, 8, 10, 12, and 23.833 hours after drug administration</time_frame>
    <description>Terminal rate constant of the analyte in plasma at steady state</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2,ss (Fasted Conditions)</measure>
    <time_frame>Serial pharmacokinetic blood samples collected before drug administration, 1, 2, 2.5, 3, 4, 6, 8, 10, 12, and 23.833 hours after drug administration</time_frame>
    <description>Terminal half-life of the analyte in plasma at steady state</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MRTpo,ss (Fasted Conditions)</measure>
    <time_frame>Serial pharmacokinetic blood samples collected before drug administration, 1, 2, 2.5, 3, 4, 6, 8, 10, 12, and 23.833 hours after drug administration</time_frame>
    <description>Mean residence time of the analyte in the body at steady state after oral administration</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Treatment sequence A</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>V4: PPX ER 1.5mg x 1 fed, V5: PPX ER 0.375mg x 4 fed, V6:: PPX ER 1.5mg x 1 fasted, V5: PPX ER 0.375mg x 4 fasted</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment sequence B</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>V4: PPX ER 0.375mg x 4 fed, V5: PPX ER 1.5mg x 1 fed, V6:: PPX ER 0.375mg x 4 fasted, V5: PPX ER 1.5mg x 1 fasted</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PPX ER</intervention_name>
    <description>PPX ER 0.375mg - 1.5mg for 32 days totally</description>
    <arm_group_label>Treatment sequence A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PPX ER</intervention_name>
    <description>PPX ER 0.375mg - 1.5mg for 32 days totally</description>
    <arm_group_label>Treatment sequence B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Japanese healthy male

          -  20 to 40 years of age

          -  body mass index (BMI) between 17.6 and 26.4 kg/m2 (BMI calculation: weight in
             kilograms divided by the square of height in meters)

        Exclusion criteria:

          1. Any clinical relevance findings of the medical examination as follows

               1. Blood pressure (systolic blood pressure is lower than 110 mmHg and diastolic
                  blood pressure is lower than 60 mmHg at the screening in either a supine or a
                  sitting position),

               2. pulse rate,

               3. electrocardiogram [ECG]

               4. laboratory test parameters) of clinical relevance

          2. Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic,
             immunological or hormonal disorders

          3. Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or
             neurological disorders

          4. History of orthostatic hypotension, fainting spells or blackouts

          5. Chronic or acute infections
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>248.677.001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sumida-ku, Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 5, 2010</study_first_submitted>
  <study_first_submitted_qc>May 6, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 7, 2010</study_first_posted>
  <results_first_submitted>May 30, 2011</results_first_submitted>
  <results_first_submitted_qc>May 30, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 27, 2011</results_first_posted>
  <last_update_submitted>June 3, 2014</last_update_submitted>
  <last_update_submitted_qc>June 3, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 9, 2014</last_update_posted>
  <responsible_party>
    <name_title>Boehringer Ingelheim, Study Chair</name_title>
    <organization>Boehringer Ingelheim</organization>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pramipexole</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Treatment Sequence A</title>
          <description>1.5 mg x 1 tablet once daily (q.d.) fed -&gt; 0.375 mg x 4 tablets q.d. fed -&gt; 1.5 mg x 1 tablet q.d. fasted -&gt; 0.375 mg x 4 tablets q.d. fasted</description>
        </group>
        <group group_id="P2">
          <title>Treatment Sequence B</title>
          <description>0.375 mg x 4 tablets q.d. fed -&gt; 1.5 mg x 1 tablet q.d. fed -&gt; 0.375 mg x 4 tablets q.d. fasted -&gt; 1.5 mg x 1 tablet q.d. fasted</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Up-titration Period (10 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Crossover Period 1 (5 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Crossover Period 2 (5 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Crossover Period 3 (5 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Crossover Period 4 (5 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Down-titration Period (1 Day)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>End of Study (All Patients)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Treatment Sequence A</title>
          <description>1.5 mg x 1 tablet q.d. fed -&gt; 0.375 mg x 4 tablets q.d. fed -&gt; 1.5 mg x 1 tablet q.d. fasted -&gt; 0.375 mg x 4 tablets q.d. fasted</description>
        </group>
        <group group_id="B2">
          <title>Treatment Sequence B</title>
          <description>0.375 mg x 4 tablets q.d. fed -&gt; 1.5 mg x 1 tablet q.d. fed -&gt; 0.375 mg x 4 tablets q.d. fasted -&gt; 1.5 mg x 1 tablet q.d. fasted</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="14"/>
            <count group_id="B2" value="14"/>
            <count group_id="B3" value="28"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29.2" spread="4.8"/>
                    <measurement group_id="B2" value="29.1" spread="5.4"/>
                    <measurement group_id="B3" value="29.1" spread="5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>AUCτ,ss (Fed Conditions)</title>
        <description>Area under the concentration-time curve of the analyte in plasma at steady state over a uniform dosing interval τ</description>
        <time_frame>Serial pharmacokinetic blood samples collected before drug administration, 1, 2, 2.5, 3, 4, 6, 8, 10, 12, and 23.833 hours after drug administration</time_frame>
        <population>One subject who discontinued the study on Day 1 of Visit 4 (the first day of the first crossover period) was excluded from Pharmacokinetic data set</population>
        <group_list>
          <group group_id="O1">
            <title>Pramipexole ER 1.5 mg x 1 Tablet q.d. in Fed</title>
            <description>Pramipexole ER 1.5 mg x 1 tablet once a day (q.d.) under fed conditions</description>
          </group>
          <group group_id="O2">
            <title>Pramipexole ER 0.375 mg x 4 Tablets q.d. in Fed</title>
            <description>Pramipexole ER 0.375 mg x 4 tablets once a day (q.d.) under fed conditions</description>
          </group>
        </group_list>
        <measure>
          <title>AUCτ,ss (Fed Conditions)</title>
          <description>Area under the concentration-time curve of the analyte in plasma at steady state over a uniform dosing interval τ</description>
          <population>One subject who discontinued the study on Day 1 of Visit 4 (the first day of the first crossover period) was excluded from Pharmacokinetic data set</population>
          <units>ng·h/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.7" spread="5.89"/>
                    <measurement group_id="O2" value="32.3" spread="5.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Bioequivalence between pramipexole ER 1.5 mg x 1 tablet q.d. and pramipexole ER 0.375 mg x 4 tablets q.d. in fed condition</non_inferiority_desc>
            <param_type>Test/Reference Ratio of the mean x 100</param_type>
            <param_value>104.2</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>98.3</ci_lower_limit>
            <ci_upper_limit>110.3</ci_upper_limit>
            <estimate_desc>Bioequivalence is established when 90% Confidence Interval falls within 80 - 125</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cmax,ss (Fed Conditions)</title>
        <description>maximum measured concentration of the analyte in plasma at steady state over a uniform dosing interval τ</description>
        <time_frame>Serial pharmacokinetic blood samples collected before drug administration, 1, 2, 2.5, 3, 4, 6, 8, 10, 12, and 23.833 hours after drug administration</time_frame>
        <population>One subject who discontinued the study on Day 1 of Visit 4 (the first day of the first crossover period) was excluded from Pharmacokinetic data set</population>
        <group_list>
          <group group_id="O1">
            <title>Pramipexole ER 1.5 mg x 1 Tablet q.d. in Fed</title>
            <description>Pramipexole ER 1.5 mg x 1 tablet once a day (q.d.) under fed conditions</description>
          </group>
          <group group_id="O2">
            <title>Pramipexole ER 0.375 mg x 4 Tablets q.d. in Fed</title>
            <description>Pramipexole ER 0.375 mg x 4 tablets once a day (q.d.) under fed conditions</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax,ss (Fed Conditions)</title>
          <description>maximum measured concentration of the analyte in plasma at steady state over a uniform dosing interval τ</description>
          <population>One subject who discontinued the study on Day 1 of Visit 4 (the first day of the first crossover period) was excluded from Pharmacokinetic data set</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.24" spread="0.290"/>
                    <measurement group_id="O2" value="2.13" spread="0.255"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Bioequivalence between pramipexole ER 1.5 mg x 1 tablet q.d. and pramipexole ER 0.375 mg x 4 tablets q.d. in fed condition</non_inferiority_desc>
            <param_type>Test/Reference Ratio of the mean x 100</param_type>
            <param_value>104.8</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>100.1</ci_lower_limit>
            <ci_upper_limit>109.8</ci_upper_limit>
            <estimate_desc>Bioequivalence is established when 90% Confidence Interval falls within 80 - 125</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cτ,ss (Fed Conditions)</title>
        <description>Concentration of the analyte in plasma at time τ at steady state</description>
        <time_frame>pharmacokinetic blood samples collected at τ (23.833 hours) after drug administration</time_frame>
        <population>One subject who discontinued the study on Day 1 of Visit 4 (the first day of the first crossover period) was excluded from Pharmacokinetic data set</population>
        <group_list>
          <group group_id="O1">
            <title>Pramipexole ER 1.5 mg x 1 Tablet q.d. in Fed</title>
            <description>Pramipexole ER 1.5 mg x 1 tablet once a day (q.d.) under fed conditions</description>
          </group>
          <group group_id="O2">
            <title>Pramipexole ER 0.375 mg x 4 Tablets q.d. in Fed</title>
            <description>Pramipexole ER 0.375 mg x 4 tablets once a day (q.d.) under fed conditions</description>
          </group>
        </group_list>
        <measure>
          <title>Cτ,ss (Fed Conditions)</title>
          <description>Concentration of the analyte in plasma at time τ at steady state</description>
          <population>One subject who discontinued the study on Day 1 of Visit 4 (the first day of the first crossover period) was excluded from Pharmacokinetic data set</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.711" spread="0.184"/>
                    <measurement group_id="O2" value="0.656" spread="0.217"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Bioequivalence between pramipexole ER 1.5 mg x 1 tablet q.d. and pramipexole ER 0.375 mg x 4 tablets q.d. in fed condition</non_inferiority_desc>
            <param_type>Test/Reference Ratio of the mean x 100</param_type>
            <param_value>108.31</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>95.634</ci_lower_limit>
            <ci_upper_limit>122.676</ci_upper_limit>
            <estimate_desc>Bioequivalence is established when 90% Confidence Interval falls within 80 - 125</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cmin,ss (Fed Conditions)</title>
        <description>Minimum measured concentration of the analyte in plasma at steady state over a uniform dosing interval τ</description>
        <time_frame>Serial pharmacokinetic blood samples collected before drug administration, 1, 2, 2.5, 3, 4, 6, 8, 10, 12, and 23.833 hours after drug administration</time_frame>
        <population>One subject who discontinued the study on Day 1 of Visit 4 (the first day of the first crossover period) was excluded from Pharmacokinetic data set</population>
        <group_list>
          <group group_id="O1">
            <title>Pramipexole ER 1.5 mg x 1 Tablet q.d. in Fed</title>
            <description>Pramipexole ER 1.5 mg x 1 tablet once a day (q.d.) under fed conditions</description>
          </group>
          <group group_id="O2">
            <title>Pramipexole ER 0.375 mg x 4 Tablets q.d. in Fed</title>
            <description>Pramipexole ER 0.375 mg x 4 tablets once a day (q.d.) under fed conditions</description>
          </group>
        </group_list>
        <measure>
          <title>Cmin,ss (Fed Conditions)</title>
          <description>Minimum measured concentration of the analyte in plasma at steady state over a uniform dosing interval τ</description>
          <population>One subject who discontinued the study on Day 1 of Visit 4 (the first day of the first crossover period) was excluded from Pharmacokinetic data set</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.676" spread="0.195"/>
                    <measurement group_id="O2" value="0.633" spread="0.218"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Bioequivalence between pramipexole ER 1.5 mg x 1 tablet q.d. and pramipexole ER 0.375 mg x 4 tablets q.d. in fed condition</non_inferiority_desc>
            <param_type>Test/Reference Ratio of the mean x 100</param_type>
            <param_value>106.85</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>93.189</ci_lower_limit>
            <ci_upper_limit>122.251</ci_upper_limit>
            <estimate_desc>Bioequivalence is established when 90% Confidence Interval falls within 80 - 125</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tmax,ss (Fed Conditions)</title>
        <description>Time from dosing to the maximum measured concentration of the analyte in plasma at steady state over a uniform dosing interval τ</description>
        <time_frame>Serial pharmacokinetic blood samples collected before drug administration, 1, 2, 2.5, 3, 4, 6, 8, 10, 12, and 23.833 hours after drug administration</time_frame>
        <population>One subject who discontinued the study on Day 1 of Visit 4 (the first day of the first crossover period) was excluded from Pharmacokinetic data set</population>
        <group_list>
          <group group_id="O1">
            <title>Pramipexole ER 1.5 mg x 1 Tablet q.d. in Fed</title>
            <description>Pramipexole ER 1.5 mg x 1 tablet once a day (q.d.) under fed conditions</description>
          </group>
          <group group_id="O2">
            <title>Pramipexole ER 0.375 mg x 4 Tablets q.d. in Fed</title>
            <description>Pramipexole ER 0.375 mg x 4 tablets once a day (q.d.) under fed conditions</description>
          </group>
        </group_list>
        <measure>
          <title>Tmax,ss (Fed Conditions)</title>
          <description>Time from dosing to the maximum measured concentration of the analyte in plasma at steady state over a uniform dosing interval τ</description>
          <population>One subject who discontinued the study on Day 1 of Visit 4 (the first day of the first crossover period) was excluded from Pharmacokinetic data set</population>
          <units>hour</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.67" lower_limit="2.00" upper_limit="10.00"/>
                    <measurement group_id="O2" value="5.76" lower_limit="2.00" upper_limit="10.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Bioequivalence between pramipexole ER 1.5 mg x 1 tablet q.d. and pramipexole ER 0.375 mg x 4 tablets q.d. in fed condition</non_inferiority_desc>
            <param_type>Test/Reference Ratio of the mean x 100</param_type>
            <param_value>98.426</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>84.276</ci_lower_limit>
            <ci_upper_limit>112.58</ci_upper_limit>
            <estimate_desc>Bioequivalence is established when 90% Confidence Interval falls within 80 - 125</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>λz,ss (Fed Conditions)</title>
        <description>Terminal rate constant of the analyte in plasma at steady state</description>
        <time_frame>Serial pharmacokinetic blood samples collected before drug administration, 1, 2, 2.5, 3, 4, 6, 8, 10, 12, and 23.833 hours after drug administration</time_frame>
        <population>One subject who discontinued the study on Day 1 of Visit 4 (the first day of the first crossover period) was excluded from Pharmacokinetic data set</population>
        <group_list>
          <group group_id="O1">
            <title>Pramipexole ER 1.5 mg x 1 Tablet q.d. in Fed</title>
            <description>Pramipexole ER 1.5 mg x 1 tablet once a day (q.d.) under fed conditions</description>
          </group>
          <group group_id="O2">
            <title>Pramipexole ER 0.375 mg x 4 Tablets q.d. in Fed</title>
            <description>Pramipexole ER 0.375 mg x 4 tablets once a day (q.d.) under fed conditions</description>
          </group>
        </group_list>
        <measure>
          <title>λz,ss (Fed Conditions)</title>
          <description>Terminal rate constant of the analyte in plasma at steady state</description>
          <population>One subject who discontinued the study on Day 1 of Visit 4 (the first day of the first crossover period) was excluded from Pharmacokinetic data set</population>
          <units>per hour</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0609" spread="0.0170"/>
                    <measurement group_id="O2" value="0.0640" spread="0.0169"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Bioequivalence between pramipexole ER 1.5 mg x 1 tablet q.d. and pramipexole ER 0.375 mg x 4 tablets q.d. in fed condition</non_inferiority_desc>
            <param_type>Test/Reference Ratio of the mean x 100</param_type>
            <param_value>95.11</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>82.461</ci_lower_limit>
            <ci_upper_limit>109.698</ci_upper_limit>
            <estimate_desc>Bioequivalence is established when 90% Confidence Interval falls within 80 - 125</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>t1/2,ss (Fed Conditions)</title>
        <description>Terminal half-life of the analyte in plasma at steady state</description>
        <time_frame>Serial pharmacokinetic blood samples collected before drug administration, 1, 2, 2.5, 3, 4, 6, 8, 10, 12, and 23.833 hours after drug administration</time_frame>
        <population>One subject who discontinued the study on Day 1 of Visit 4 (the first day of the first crossover period) was excluded from Pharmacokinetic data set</population>
        <group_list>
          <group group_id="O1">
            <title>Pramipexole ER 1.5 mg x 1 Tablet q.d. in Fed</title>
            <description>Pramipexole ER 1.5 mg x 1 tablet once a day (q.d.) under fed conditions</description>
          </group>
          <group group_id="O2">
            <title>Pramipexole ER 0.375 mg x 4 Tablets q.d. in Fed</title>
            <description>Pramipexole ER 0.375 mg x 4 tablets once a day (q.d.) under fed conditions</description>
          </group>
        </group_list>
        <measure>
          <title>t1/2,ss (Fed Conditions)</title>
          <description>Terminal half-life of the analyte in plasma at steady state</description>
          <population>One subject who discontinued the study on Day 1 of Visit 4 (the first day of the first crossover period) was excluded from Pharmacokinetic data set</population>
          <units>hour</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.4" spread="5.02"/>
                    <measurement group_id="O2" value="10.8" spread="6.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>MRTpo,ss (Fed Conditions)</title>
        <description>Mean residence time of the analyte in the body at steady state after oral administration</description>
        <time_frame>Serial pharmacokinetic blood samples collected before drug administration, 1, 2, 2.5, 3, 4, 6, 8, 10, 12, and 23.833 hours after drug administration</time_frame>
        <population>One subject who discontinued the study on Day 1 of Visit 4 (the first day of the first crossover period) was excluded from Pharmacokinetic data set</population>
        <group_list>
          <group group_id="O1">
            <title>Pramipexole ER 1.5 mg x 1 Tablet q.d. in Fed</title>
            <description>Pramipexole ER 1.5 mg x 1 tablet once a day (q.d.) under fed conditions</description>
          </group>
          <group group_id="O2">
            <title>Pramipexole ER 0.375 mg x 4 Tablets q.d. in Fed</title>
            <description>Pramipexole ER 0.375 mg x 4 tablets once a day (q.d.) under fed conditions</description>
          </group>
        </group_list>
        <measure>
          <title>MRTpo,ss (Fed Conditions)</title>
          <description>Mean residence time of the analyte in the body at steady state after oral administration</description>
          <population>One subject who discontinued the study on Day 1 of Visit 4 (the first day of the first crossover period) was excluded from Pharmacokinetic data set</population>
          <units>hour</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.1" spread="6.08"/>
                    <measurement group_id="O2" value="18.4" spread="7.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Bioequivalence between pramipexole ER 1.5 mg x 1 tablet q.d. and pramipexole ER 0.375 mg x 4 tablets q.d. in fed condition</non_inferiority_desc>
            <param_type>Test/Reference Ratio of the mean x 100</param_type>
            <param_value>104.07</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>91.585</ci_lower_limit>
            <ci_upper_limit>118.263</ci_upper_limit>
            <estimate_desc>Bioequivalence is established when 90% Confidence Interval falls within 80 - 125</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUCτ,ss (Fasted Conditions)</title>
        <description>Area under the concentration-time curve of the analyte in plasma at steady state over a uniform dosing interval τ</description>
        <time_frame>Serial pharmacokinetic blood samples collected before drug administration, 1, 2, 2.5, 3, 4, 6, 8, 10, 12, and 23.833 hours after drug administration</time_frame>
        <population>One subject who discontinued the study on Day 1 of Visit 4 (the first day of the first crossover period) was excluded from Pharmacokinetic data set</population>
        <group_list>
          <group group_id="O1">
            <title>Pramipexole ER 1.5 mg x 1 Tablet q.d. in Fasted</title>
            <description>Pramipexole ER 1.5 mg x 1 tablet once a day (q.d.) under fasted conditions</description>
          </group>
          <group group_id="O2">
            <title>Pramipexole ER 0.375 mg x 4 Tablets q.d. in Fasted</title>
            <description>Pramipexole ER 0.375 mg x 4 tablets once a day (q.d.) under fasted conditions</description>
          </group>
        </group_list>
        <measure>
          <title>AUCτ,ss (Fasted Conditions)</title>
          <description>Area under the concentration-time curve of the analyte in plasma at steady state over a uniform dosing interval τ</description>
          <population>One subject who discontinued the study on Day 1 of Visit 4 (the first day of the first crossover period) was excluded from Pharmacokinetic data set</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.4" spread="7.37"/>
                    <measurement group_id="O2" value="33.6" spread="5.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Bioequivalence between pramipexole ER 1.5 mg x 1 tablet q.d. and pramipexole ER 0.375 mg x 4 tablets q.d. in fasted condition</non_inferiority_desc>
            <param_type>Test/Reference Ratio of the mean x 100</param_type>
            <param_value>93.6</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>86.9</ci_lower_limit>
            <ci_upper_limit>100.8</ci_upper_limit>
            <estimate_desc>Bioequivalence is established when 90% Confidence Interval falls within 80 - 125</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cmax,ss (Fasted Conditions)</title>
        <description>maximum measured concentration of the analyte in plasma at steady state over a uniform dosing interval τ</description>
        <time_frame>Serial pharmacokinetic blood samples collected before drug administration, 1, 2, 2.5, 3, 4, 6, 8, 10, 12, and 23.833 hours after drug administration</time_frame>
        <population>One subject who discontinued the study on Day 1 of Visit 4 (the first day of the first crossover period) was excluded from Pharmacokinetic data set</population>
        <group_list>
          <group group_id="O1">
            <title>Pramipexole ER 1.5 mg x 1 Tablet q.d. in Fasted</title>
            <description>Pramipexole ER 1.5 mg x 1 tablet once a day (q.d.) under fasted conditions</description>
          </group>
          <group group_id="O2">
            <title>Pramipexole ER 0.375 mg x 4 Tablets q.d. in Fasted</title>
            <description>Pramipexole ER 0.375 mg x 4 tablets once a day (q.d.) under fasted conditions</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax,ss (Fasted Conditions)</title>
          <description>maximum measured concentration of the analyte in plasma at steady state over a uniform dosing interval τ</description>
          <population>One subject who discontinued the study on Day 1 of Visit 4 (the first day of the first crossover period) was excluded from Pharmacokinetic data set</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.13" spread="0.359"/>
                    <measurement group_id="O2" value="2.12" spread="0.305"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Bioequivalence between pramipexole ER 1.5 mg x 1 tablet q.d. and pramipexole ER 0.375 mg x 4 tablets q.d. in fasted condition</non_inferiority_desc>
            <param_type>Test/Reference Ratio of the mean x 100</param_type>
            <param_value>100.2</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>94.0</ci_lower_limit>
            <ci_upper_limit>106.7</ci_upper_limit>
            <estimate_desc>Bioequivalence is established when 90% Confidence Interval falls within 80 - 125</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cτ,ss (Fasted Conditions)</title>
        <description>Concentration of the analyte in plasma at time τ at steady state</description>
        <time_frame>pharmacokinetic blood samples collected at τ (23.833 hours) after drug administration</time_frame>
        <population>One subject who discontinued the study on Day 1 of Visit 4 (the first day of the first crossover period) was excluded from Pharmacokinetic data set</population>
        <group_list>
          <group group_id="O1">
            <title>Pramipexole ER 1.5 mg x 1 Tablet q.d. in Fasted</title>
            <description>Pramipexole ER 1.5 mg x 1 tablet once a day (q.d.) under fasted conditions</description>
          </group>
          <group group_id="O2">
            <title>Pramipexole ER 0.375 mg x 4 Tablets q.d. in Fasted</title>
            <description>Pramipexole ER 0.375 mg x 4 tablets once a day (q.d.) under fasted conditions</description>
          </group>
        </group_list>
        <measure>
          <title>Cτ,ss (Fasted Conditions)</title>
          <description>Concentration of the analyte in plasma at time τ at steady state</description>
          <population>One subject who discontinued the study on Day 1 of Visit 4 (the first day of the first crossover period) was excluded from Pharmacokinetic data set</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.654" spread="0.342"/>
                    <measurement group_id="O2" value="0.757" spread="0.283"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Bioequivalence between pramipexole ER 1.5 mg x 1 tablet q.d. and pramipexole ER 0.375 mg x 4 tablets q.d. in fasted condition</non_inferiority_desc>
            <param_type>Test/Reference Ratio of the mean x 100</param_type>
            <param_value>86.57</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>73.583</ci_lower_limit>
            <ci_upper_limit>101.854</ci_upper_limit>
            <estimate_desc>Bioequivalence is established when 90% Confidence Interval falls within 80 - 125</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cmin,ss (Fasted Conditions)</title>
        <description>Minimum measured concentration of the analyte in plasma at steady state over a uniform dosing interval τ</description>
        <time_frame>Serial pharmacokinetic blood samples collected before drug administration, 1, 2, 2.5, 3, 4, 6, 8, 10, 12, and 23.833 hours after drug administration</time_frame>
        <population>One subject who discontinued the study on Day 1 of Visit 4 (the first day of the first crossover period) was excluded from Pharmacokinetic data set</population>
        <group_list>
          <group group_id="O1">
            <title>Pramipexole ER 1.5 mg x 1 Tablet q.d. in Fasted</title>
            <description>Pramipexole ER 1.5 mg x 1 tablet once a day (q.d.) under fasted conditions</description>
          </group>
          <group group_id="O2">
            <title>Pramipexole ER 0.375 mg x 4 Tablets q.d. in Fasted</title>
            <description>Pramipexole ER 0.375 mg x 4 tablets once a day (q.d.) under fasted conditions</description>
          </group>
        </group_list>
        <measure>
          <title>Cmin,ss (Fasted Conditions)</title>
          <description>Minimum measured concentration of the analyte in plasma at steady state over a uniform dosing interval τ</description>
          <population>One subject who discontinued the study on Day 1 of Visit 4 (the first day of the first crossover period) was excluded from Pharmacokinetic data set</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.654" spread="0.342"/>
                    <measurement group_id="O2" value="0.757" spread="0.283"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Bioequivalence between pramipexole ER 1.5 mg x 1 tablet q.d. and pramipexole ER 0.375 mg x 4 tablets q.d. in fasted condition</non_inferiority_desc>
            <param_type>Test/Reference Ratio of the mean x 100</param_type>
            <param_value>86.57</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>73.583</ci_lower_limit>
            <ci_upper_limit>101.854</ci_upper_limit>
            <estimate_desc>Bioequivalence is established when 90% Confidence Interval falls within 80 - 125</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tmax,ss (Fasted Conditions)</title>
        <description>Time from dosing to the maximum measured concentration of the analyte in plasma at steady state over a uniform dosing interval τ</description>
        <time_frame>Serial pharmacokinetic blood samples collected before drug administration, 1, 2, 2.5, 3, 4, 6, 8, 10, 12, and 23.833 hours after drug administration</time_frame>
        <population>One subject who discontinued the study on Day 1 of Visit 4 (the first day of the first crossover period) was excluded from Pharmacokinetic data set</population>
        <group_list>
          <group group_id="O1">
            <title>Pramipexole ER 1.5 mg x 1 Tablet q.d. in Fasted</title>
            <description>Pramipexole ER 1.5 mg x 1 tablet once a day (q.d.) under fasted conditions</description>
          </group>
          <group group_id="O2">
            <title>Pramipexole ER 0.375 mg x 4 Tablets q.d. in Fasted</title>
            <description>Pramipexole ER 0.375 mg x 4 tablets once a day (q.d.) under fasted conditions</description>
          </group>
        </group_list>
        <measure>
          <title>Tmax,ss (Fasted Conditions)</title>
          <description>Time from dosing to the maximum measured concentration of the analyte in plasma at steady state over a uniform dosing interval τ</description>
          <population>One subject who discontinued the study on Day 1 of Visit 4 (the first day of the first crossover period) was excluded from Pharmacokinetic data set</population>
          <units>hour</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.24" lower_limit="2.00" upper_limit="8.00"/>
                    <measurement group_id="O2" value="4.28" lower_limit="2.50" upper_limit="8.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Bioequivalence between pramipexole ER 1.5 mg x 1 tablet q.d. and pramipexole ER 0.375 mg x 4 tablets q.d. in fasted condition</non_inferiority_desc>
            <param_type>Test/Reference Ratio of the mean x 100</param_type>
            <param_value>99.069</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>80.688</ci_lower_limit>
            <ci_upper_limit>117.45</ci_upper_limit>
            <estimate_desc>Bioequivalence is established when 90% Confidence Interval falls within 80 - 125</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>λz,ss (Fasted Conditions)</title>
        <description>Terminal rate constant of the analyte in plasma at steady state</description>
        <time_frame>Serial pharmacokinetic blood samples collected before drug administration, 1, 2, 2.5, 3, 4, 6, 8, 10, 12, and 23.833 hours after drug administration</time_frame>
        <population>One subject who discontinued the study on Day 1 of Visit 4 (the first day of the first crossover period) was excluded from Pharmacokinetic data set</population>
        <group_list>
          <group group_id="O1">
            <title>Pramipexole ER 1.5 mg x 1 Tablet q.d. in Fasted</title>
            <description>Pramipexole ER 1.5 mg x 1 tablet once a day (q.d.) under fasted conditions</description>
          </group>
          <group group_id="O2">
            <title>Pramipexole ER 0.375 mg x 4 Tablets q.d. in Fasted</title>
            <description>Pramipexole ER 0.375 mg x 4 tablets once a day (q.d.) under fasted conditions</description>
          </group>
        </group_list>
        <measure>
          <title>λz,ss (Fasted Conditions)</title>
          <description>Terminal rate constant of the analyte in plasma at steady state</description>
          <population>One subject who discontinued the study on Day 1 of Visit 4 (the first day of the first crossover period) was excluded from Pharmacokinetic data set</population>
          <units>/hour</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0520" spread="0.0275"/>
                    <measurement group_id="O2" value="0.0474" spread="0.0239"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Bioequivalence between pramipexole ER 1.5 mg x 1 tablet q.d. and pramipexole ER 0.375 mg x 4 tablets q.d. in fasted condition</non_inferiority_desc>
            <param_type>Test/Reference Ratio of the mean x 100</param_type>
            <param_value>109.48</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>89.571</ci_lower_limit>
            <ci_upper_limit>133.811</ci_upper_limit>
            <estimate_desc>Bioequivalence is established when 90% Confidence Interval falls within 80 - 125</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>t1/2,ss (Fasted Conditions)</title>
        <description>Terminal half-life of the analyte in plasma at steady state</description>
        <time_frame>Serial pharmacokinetic blood samples collected before drug administration, 1, 2, 2.5, 3, 4, 6, 8, 10, 12, and 23.833 hours after drug administration</time_frame>
        <population>One subject who discontinued the study on Day 1 of Visit 4 (the first day of the first crossover period) was excluded from Pharmacokinetic data set</population>
        <group_list>
          <group group_id="O1">
            <title>Pramipexole ER 1.5 mg x 1 Tablet q.d. in Fasted</title>
            <description>Pramipexole ER 1.5 mg x 1 tablet once a day (q.d.) under fasted conditions</description>
          </group>
          <group group_id="O2">
            <title>Pramipexole ER 0.375 mg x 4 Tablets q.d. in Fasted</title>
            <description>Pramipexole ER 0.375 mg x 4 tablets once a day (q.d.) under fasted conditions</description>
          </group>
        </group_list>
        <measure>
          <title>t1/2,ss (Fasted Conditions)</title>
          <description>Terminal half-life of the analyte in plasma at steady state</description>
          <population>One subject who discontinued the study on Day 1 of Visit 4 (the first day of the first crossover period) was excluded from Pharmacokinetic data set</population>
          <units>hour</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.3" spread="9.82"/>
                    <measurement group_id="O2" value="14.6" spread="10.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>MRTpo,ss (Fasted Conditions)</title>
        <description>Mean residence time of the analyte in the body at steady state after oral administration</description>
        <time_frame>Serial pharmacokinetic blood samples collected before drug administration, 1, 2, 2.5, 3, 4, 6, 8, 10, 12, and 23.833 hours after drug administration</time_frame>
        <population>One subject who discontinued the study on Day 1 of Visit 4 (the first day of the first crossover period) was excluded from Pharmacokinetic data set</population>
        <group_list>
          <group group_id="O1">
            <title>Pramipexole ER 1.5 mg x 1 Tablet q.d. in Fasted</title>
            <description>Pramipexole ER 1.5 mg x 1 tablet once a day (q.d.) under fasted conditions</description>
          </group>
          <group group_id="O2">
            <title>Pramipexole ER 0.375 mg x 4 Tablets q.d. in Fasted</title>
            <description>Pramipexole ER 0.375 mg x 4 tablets once a day (q.d.) under fasted conditions</description>
          </group>
        </group_list>
        <measure>
          <title>MRTpo,ss (Fasted Conditions)</title>
          <description>Mean residence time of the analyte in the body at steady state after oral administration</description>
          <population>One subject who discontinued the study on Day 1 of Visit 4 (the first day of the first crossover period) was excluded from Pharmacokinetic data set</population>
          <units>hour</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.2" spread="13.1"/>
                    <measurement group_id="O2" value="22.9" spread="13.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Bioequivalence between pramipexole ER 1.5 mg x 1 tablet q.d. and pramipexole ER 0.375 mg x 4 tablets q.d. in fasted condition</non_inferiority_desc>
            <param_type>Test/Reference Ratio of the mean x 100</param_type>
            <param_value>92.63</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>77.871</ci_lower_limit>
            <ci_upper_limit>110.185</ci_upper_limit>
            <estimate_desc>Bioequivalence is established when 90% Confidence Interval falls within 80 - 125</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>32 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Up-titration</title>
          <description>Up-titration to 0.75mg (10 days)</description>
        </group>
        <group group_id="E2">
          <title>1.5 mg q.d. Fed</title>
          <description>1.5 mg x 1 tablet q.d. or 0.375 mg x 4 tablets q.d. in fed condition (10days in crossover)</description>
        </group>
        <group group_id="E3">
          <title>1.5 mg q.d. Fast</title>
          <description>1.5 mg x 1 tablet q.d. or 0.375 mg x 4 tablets q.d. in fast condition (10 days in crossover)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 13.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Epigastric discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Boehringer Ingelheim Call Center</name_or_title>
      <organization>Boehringer Ingelheim Pharmaceuticals</organization>
      <phone>1-800-243-0127</phone>
      <email>clintriage.rdg@boehringer-ingelheim.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

